0001140361-18-012009.txt : 20180305
0001140361-18-012009.hdr.sgml : 20180305
20180305165622
ACCESSION NUMBER: 0001140361-18-012009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180301
FILED AS OF DATE: 20180305
DATE AS OF CHANGE: 20180305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RAY DEBANJAN
CENTRAL INDEX KEY: 0001706863
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 18666937
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD, SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2018-03-01
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001706863
RAY DEBANJAN
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
Common Stock
2018-03-01
4
M
0
13000
1.2599
A
17741
D
Common Stock
2018-03-01
4
S
0
13000
29.4032
D
4741
D
Common Stock
2018-03-02
4
M
0
5515
1.2599
A
10256
D
Common Stock
2018-03-02
4
S
0
5515
30.059
D
4741
D
Common Stock
2018-03-02
4
M
0
14485
1.1339
A
19226
D
Common Stock
2018-03-02
4
S
0
12541
30.411
D
6685
D
Common Stock
2018-03-02
4
S
0
1944
31.015
D
4741
D
Stock Option (Right to Buy)
1.2599
2018-03-01
4
M
0
13000
0.00
D
2023-12-10
Common Stock
13000
20225
D
Stock Option (Right to Buy)
1.2599
2018-03-02
4
M
0
5515
0.00
D
2023-12-10
Common Stock
5515
14710
D
Stock Option (Right to Buy)
1.1339
2018-03-02
4
M
0
14485
0.00
D
2021-09-13
Common Stock
14485
20000
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.38, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
100% of the shares subject to the option are fully vested and exercisable.
/s/ Debanjan Ray
2018-03-05